BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35476234)

  • 21. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.
    Ito T; Sasano H; Tanaka M; Osamura RY; Sasaki I; Kimura W; Takano K; Obara T; Ishibashi M; Nakao K; Doi R; Shimatsu A; Nishida T; Komoto I; Hirata Y; Nakamura K; Igarashi H; Jensen RT; Wiedenmann B; Imamura M
    J Gastroenterol; 2010 Feb; 45(2):234-43. PubMed ID: 20058030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
    Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
    J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applications of a novel tumor-grading-metastasis staging system for pancreatic neuroendocrine tumors: An analysis of surgical patients from a Chinese institution.
    Yang M; Tan CL; Zhang Y; Ke NW; Zeng L; Li A; Zhang H; Xiong JJ; Guo ZH; Tian BL; Liu XB
    Medicine (Baltimore); 2016 Jul; 95(28):e4213. PubMed ID: 27428224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resectability of primary gastroenteropancreatic neuroendocrine tumor as a prognostic factor for survival.
    Medrano-Guzmán R; López-García SC; Torres-Vargas S; González-Rodríguez D; Alvarado-Cabrero I
    Cir Cir; 2011; 79(6):498-504. PubMed ID: 22169366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.
    Carlinfante G; Baccarini P; Berretti D; Cassetti T; Cavina M; Conigliaro R; De Pellegrin A; Di Tommaso L; Fabbri C; Fornelli A; Frasoldati A; Gardini G; Losi L; Maccio L; Manta R; Pagano N; Sassatelli R; Serra S; Camellini L
    Virchows Arch; 2014 Jul; 465(1):49-55. PubMed ID: 24807732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis.
    Ito T; Igarashi H; Nakamura K; Sasano H; Okusaka T; Takano K; Komoto I; Tanaka M; Imamura M; Jensen RT; Takayanagi R; Shimatsu A
    J Gastroenterol; 2015 Jan; 50(1):58-64. PubMed ID: 24499825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: A population-based study.
    Zheng Z; Chen C; Jiang L; Zhou X; Dai X; Song Y; Li Y
    Cancer Med; 2019 Dec; 8(17):7288-7298. PubMed ID: 31609098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective clinico-pathological analysis of neuroendocrine tumors of the gastrointestinal tract.
    Amarapurkar DN; Juneja MP; Patel ND; Amarapurkar AD; Amarapurkar PD
    Trop Gastroenterol; 2010; 31(2):101-4. PubMed ID: 20862983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution.
    Yang M; Zeng L; Ke NW; Tan CL; Tian BL; Liu XB; Xiang B; Zhang Y
    BMC Cancer; 2020 Sep; 20(1):906. PubMed ID: 32962649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry.
    Begum N; Maasberg S; Pascher A; Plöckinger U; Gress TM; Wurst C; Weber F; Raffel A; Krausch M; Holzer K; Bartsch DK; Musholt TJ; Keck T; Anlauf M; Rinke A; Pape UF; Goretzki PE;
    Langenbecks Arch Surg; 2020 Mar; 405(2):145-154. PubMed ID: 32372309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Grading of neuroendocrine tumors].
    Saeger W; Schnabel PA; Komminoth P
    Pathologe; 2016 Jul; 37(4):304-13. PubMed ID: 27379621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
    Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
    JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nationwide registry for patients with neuroendocrine neoplasm of pancreas, gastrointestinal tract, lungs, bronchi, or thymus in Japan.
    Masui T; Ito T; Komoto I; Kojima S; Kasai Y; Tanabe M; Hara K; Hirano S; Okusaka T; Ichikawa Y; Kinugasa Y; Kokudo N; Kudo A; Sakurai A; Sugihara K; Date H; Haruma K; Hijioka S; Hirata K; Yamano H; Sakamine M; Kikuchi T; Fukushima M; Imamura M; Uemoto S
    Int J Clin Oncol; 2022 May; 27(5):840-849. PubMed ID: 35178624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
    Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management and Survival Analysis of Gastrointestinal Neuroendocrine Tumors by Different Tumor Characteristics: Tertiary Center Experience.
    Gonulal B; Bilgic Y; Akbulut S; Karabulut E; Samdanci ET
    J Gastrointest Cancer; 2022 Dec; 53(4):915-920. PubMed ID: 34524616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EPIDEMIOLOGY OF GASTROINTESTINAL NEUROENDOCRINE TUMORS IN A U.S. COMMERCIALLY INSURED POPULATION.
    Broder MS; Cai B; Chang E; Neary MP
    Endocr Pract; 2017 Oct; 23(10):1210-1216. PubMed ID: 28704096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.
    Morin E; Cheng S; Mete O; Serra S; Araujo PB; Temple S; Cleary S; Gallinger S; Greig PD; McGilvray I; Wei A; Asa SL; Ezzat S
    Cancer Med; 2013 Oct; 2(5):701-11. PubMed ID: 24403235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms.
    Borbath I; Garcia-Carbonero R; Bikmukhametov D; Jimenez-Fonseca P; Castaño A; Barkmanova J; Sedlackova E; Kollár A; Christ E; Kaltsas G; Kos-Kudla B; Maasberg S; Verslype C; Pape UF
    Eur J Cancer; 2022 Jun; 168():80-90. PubMed ID: 35472579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.